Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Milestone Pharmaceuticals Q3 EPS $(0.34), Same YoY

Milestone Pharmaceuticals Q3 EPS $(0.34), Same YoY

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.34) per share. This is unchanged from the same period last year.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.34) per share. This is unchanged from the same period last year.

Why Avery Dennison Is Still A Buy: Analyst Highlights 40% Growth In Intelligent Labels And End To Destocking

By Shivani Kumaresan

September 5, 1:53 PM

Truist Securities analyst Michael Roxland reiterated a

AVY

Acreage Holdings Q3 Financial Results, A “Highly Attractive Positioning”

By Joana Scopel

November 7, 7:28 PM

Acreage Holdings, Inc.(CSE: ACRG.A.U, ACRG.B.U) (OTCQX: ACRHF, ACRDF), reported its financial results late Monday for the third quarter ended September 30, 2022 (“Q3 2022”).

ACRDF

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,300 Today

By Benzinga Insights

April 26, 1:00 PM

Insight Enterprises (NASDAQ:NSIT) has outperformed the market over the past 5 years by 15.04% on an annualized basis…

NSIT

Citigroup Maintains Buy on DraftKings, Lowers Price Target to $20

By Benzinga Newsdesk

July 7, 7:28 AM

Citigroup analyst Jason Bazinet maintains DraftKings (NASDAQ:DKNG) with a Buy and lowers the price target from $26 to $20.

DKNG

Milestone Pharmaceuticals Q3 EPS $(0.34), Same YoY

Related Posts

Why Avery Dennison Is Still A Buy: Analyst Highlights 40% Growth In Intelligent Labels And End To Destocking

Acreage Holdings Q3 Financial Results, A “Highly Attractive Positioning”

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,300 Today

Citigroup Maintains Buy on DraftKings, Lowers Price Target to $20